Vaccinex, Inc. (VCNX) stock
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex, Inc. grew revenue 5.4% to $601.00K over the twelve months to Dec 31, 2024. Free cash flow was -$16.21M. At the latest close the market valued the company at $3.22M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2024
Valuation
- Market cap
- $3.22M
- P/E ratio
- –
- Price to sales
- 5.36
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -502.80%
Fundamentals
- Revenue
- $601.00K
- Net income
- -$18.63M
- EPS, diluted
- -$8.88
- Free cash flow
- -$16.21M
- Diluted shares
- 3M
Trading
- Previous close
- $1.01
- Open
- $1.00
- Day's range
- $0.66 – $1.00
- Volume
- 1,180
- Average volume (20 days)
- 799
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | VCNX | S&P 500 | Difference | VCNX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | -13.0% | +3.4% | −16.4 pts | ||
| Year to date | -7.0% | +13.3% | −20.3 pts | ||
| 1 year | +108.3% | +16.6% | +91.7 pts | ||
| 3 years | -93.1% | +86.4% | −179.4 pts | -58.9% | +23.1% |
| 5 years | -99.8% | +81.9% | −181.6 pts | -69.9% | +12.7% |
Nine years at a glance
Fiscal years 2016 to 2024, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vaccinex filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- News
- Update
- News
About Vaccinex
Pharmaceutical Preparations
Vaccinex, Inc. is a clinical-stage biotechnology company that discovers and develops targeted biotherapies to address serious conditions with unmet medical needs, particularly neurodegenerative diseases, cancer, and autoimmune disorders. The company's lead product candidate is pepinemab, an antibody designed to block semaphorin 4D signaling for the treatment of Alzheimer's disease as well as head and neck, pancreatic, and breast cancers. In addition, Vaccinex utilizes its proprietary ActivMAb human antibody discovery platform to generate monoclonal antibodies targeting complex multipass membrane proteins, yielding candidates such as VX5 for autoimmune indications. The company collaborates with third-party researchers and pharmaceutical partners who evaluate its pipeline candidates in clinical trials or use its discovery platform under licensing and research agreements.
Company profile, executives and historyVaccinex stock: common questions
What is Vaccinex's stock price?
VCNX closed at $1.00 on Oct 19, 2026, down 0.99% on the day.
What is Vaccinex's market cap?
Vaccinex was worth $3.22M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is VCNX's P/E ratio?
Vaccinex lost money over the twelve months to Dec 31, 2024 (diluted EPS -$8.88), so it has no meaningful P/E ratio.
How much revenue does Vaccinex make?
Vaccinex reported revenue of $601.00K for the twelve months to Dec 31, 2024, up 5.4% from a year earlier.
Does Vaccinex pay a dividend?
No. Vaccinex has not paid a cash dividend over the last twelve months.
How has VCNX stock performed over the past year?
Including dividends, VCNX returned +108.3% over the past year, against +16.6% for the S&P 500.
Who are Vaccinex's competitors?
Companies most similar to Vaccinex by business, industry and size include GOVX, ERNA, RLYB, YARW, MNOV.
See a number that looks wrong?